Liquidia Names Gerald M. O’Brien, MD, as Vice President, Pulmonary Clinical Development
October 05 2020 - 7:15AM
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical
biopharmaceutical company focused on the development and
commercialization of novel products using its proprietary
PRINT® technology, today announced the appointment of Dr.
Gerald M. O’Brien as Vice President, Pulmonary Clinical
Development, effective immediately.
“Jerry is an accomplished pulmonary critical care expert who has
dedicated his career to the treatment of patients and the
advancement of respiratory therapeutics that address unmet medical
needs. Jerry’s expertise further augments our team’s ability to
support pulmonary arterial hypertension (PAH) patients and the PAH
community as a whole,” said Tushar Shah, MD, Chief Medical Officer
and Head of R&D at Liquidia. “In this newly created
position, Jerry will take a leading role in clinical development
efforts for the company’s pulmonary programs. We welcome Jerry to
the Liquidia team and look forward to his contributions to our
near-term deliverables and long-term strategy.”
Dr. O’Brien joins Liquidia with 25 years of medical practice
experience including 10 years in an academic medical center and 15
years in a large community-based private practice. His career has
been centered around the treatment of patients with advanced lung
disease, initially as founder of the TEMPLE Lung Transplant Program
and Lung Volume Reduction Program and then as founder and director
of the Pulmonary Hypertension Center in Delaware. Dr. O’Brien was
also the founder of the Interventional Pulmonary Program at the
Helen Graham Cancer Center, a National Cancer Institute Community
Cancer Center in Delaware.
Prior to Liquidia, Dr. O’Brien was the Vice President of
Development at Complexa Inc., where he led the execution of PRIMEx,
a phase 2/3 trial for the treatment of PAH. He also previously
served as the Senior Director of Medical Affairs and the Director
of Medical Affairs at AstraZeneca and Bayer Pharmaceuticals,
respectively.
About LiquidiaLiquidia is a
late-stage clinical biopharmaceutical company focused on the
development and commercialization of novel products using its
proprietary PRINT® technology to transform the lives of patients.
PRINT is a particle engineering platform that enables precise
production of uniform drug particles designed to improve the
safety, efficacy and performance of a wide range of therapies.
Currently, Liquidia is focused on the development of two
product candidates for which it holds worldwide commercial rights:
LIQ861 for the treatment of pulmonary arterial hypertension (PAH)
and LIQ865 for the treatment of local post-operative
pain. Liquidia is headquartered in Research Triangle
Park, NC. For more information, please
visit www.liquidia.com.
Cautionary Statements Regarding Forward-Looking
Statements
This press release may include forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release other than
statements of historical facts, including statements regarding our
future results of operations and financial position, our strategic
and financial initiatives, our business strategy and plans and our
objectives for future operations, are forward-looking statements.
Such forward-looking statements, including statements regarding
clinical trials, clinical studies and other clinical work
(including the funding therefor, anticipated patient enrollment,
safety data, study data, trial outcomes, timing or associated
costs), regulatory applications and related timelines, including
potential U.S. Food and Drug Administration (FDA)
approval of the New Drug Application (NDA) for LIQ861, the timeline
or outcome related to our patent litigation pending in
the U.S. District Court for the District of Delaware or
two petitions for inter partes review with the Patent
Trial and Appeal Board, the issuance of patents by the USPTO and
our ability to execute on our strategic or financial initiatives,
involve significant risks and uncertainties and actual results
could differ materially from those expressed or implied herein. The
words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “would,” and similar expressions are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy, short-term and long-term business
operations and objectives and financial needs. These
forward-looking statements are subject to a number of risks
discussed in our and Liquidia Corporation’s filings with
the Securities and Exchange Commission, including the risk
that our proposed acquisition of RareGen, LLC is not
consummated or that the expected benefits and synergies from the
proposed acquisition are not realized, the impact of the
coronavirus (COVID-19) outbreak on our company and our financial
condition and results of operations, as well as a number of
uncertainties and assumptions. Moreover, we operate in a very
competitive and rapidly changing environment and our industry has
inherent risks. New risks emerge from time to time. It is not
possible for our management to predict all risks, nor can we assess
the impact of all factors on our business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements we may make. In light of these risks, uncertainties and
assumptions, the future events discussed in this press release may
not occur and actual results could differ materially and adversely
from those anticipated or implied in the forward-looking
statements. Nothing in this press release should be regarded as a
representation by any person that these goals will be achieved, and
we undertake no duty to update our goals or to update or alter any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact
InformationMedia:Michael ParksCorporate
Communications484.356.7105michael.parks@liquidia.com
Investors:Jason AdairVice President, Corporate
Development and Strategy919.328.4400jason.adair@liquidia.com
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Sep 2023 to Sep 2024